CAXTON CORP - Stock Holdings in 13F Filings (SEC)

Updated on March 15, 2026.

Based on 13F Filings filed with the SEC on February 13, 2026, for the 2025 Q4 period, CAXTON CORP held in its portfolio 11 assets valued at $4,279,210 (i.e. $4.28M).

The most valuable assets in the portfolio included: SPDR GOLD TR ($2.76M), BERKSHIRE HATHAWAY INC DEL ($356.77K), and SPYRE THERAPEUTICS INC ($292.19K).

The chart below shows the top 10 valuable assets, and the table below shows the top 11 valuable assets.

You can see similar for other investment managers.

Related Topics: SEC Topic List.

Data Source: SEC.

Top Valuable Stocks in CAXTON CORP Portfolio

SPDR GOLD TR

BERKSHIRE HATHAWAY INC DEL

SPYRE THERAPEUTICS INC

MIND MEDICINE MINDMED INC

KYVERNA THERAPEUTICS INC

COMPASS THERAPEUTICS INC

LEXEO THERAPEUTICS INC

X4 PHARMACEUTICALS INC

INHIBIKASE THERAPEUTICS INC

SAB BIOTHERAPEUTICS INC

CAXTON CORP - Stock Holdings in 13F Filings (SEC)

Items per page:

0 of 0

Name of Issuer	No. of Shares	Value ($)	Class
SPDR GOLD TR	6964	2759901	GOLD SHS
BERKSHIRE HATHAWAY INC DEL	710	356771	CL B NEW
SPYRE THERAPEUTICS INC	8919	292194	COM NEW
MIND MEDICINE MINDMED INC	15688	210058	COM NEW
KYVERNA THERAPEUTICS INC	18773	176468	COM
COMPASS THERAPEUTICS INC	29495	158386	COM
LEXEO THERAPEUTICS INC	13943	138453	COM
X4 PHARMACEUTICALS INC	15557	62227	COM NEW
INHIBIKASE THERAPEUTICS INC	28453	58328	COM NEW
SAB BIOTHERAPEUTICS INC	10527	39371	COM NEW
CONTEXT THERAPEUTICS INC	18403	27053	COM